PCK's Principal Activity is the development and commercialisation of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-36.63%|
|vs ASX 200 (1yr)||-37.09%|
PainChek Ltd (PCK) is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. PCK is involved in provision of pain management and better medication for residents living with dementia and other communication difficulties. The company has obtained regulatory clearance in Australia and Europe.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Ms Cynthia Payne||Non-Executive Director||Mar 2022||
Ms Cynthia Payne
Ms Payne brings 30 years executive leadership experience as well as board and operational experience in residential and home aged care services in Australia. That experience includes over 16 years as CEO for a large private aged care Provider in NSW and before that head of operation manager for a large Not for Profit with home care, residential and retirement living portfolios. She is the founder and Managing Director of Anchor Excellence, a consultancy firm in the aged care services industry in Australia that advises boards and management on operational and compliance best practices. Ms Payne is currently a board advisor to Total Constructions Pty Ltd, a former Director of the Heart Foundation and past Chair of Business Excellence Australia. She is a Certified Chair with The Board Advisory centre.
|Ms Sally McDow||Company Secretary||Jun 2021|
|Mr Philip Daffas||Chief Executive Officer,Managing Director||Sep 2016||
Mr Philip Daffas
Chief Executive Officer,Managing Director
Mr Daffas is a global business leader and people manager with an international career spanning more than 25 years with leading blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector on a global basis. Philip's earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio-Rad Laboratories and CEO of Applied Physiology, an Australian software start up company in the intensive care monitoring sector.
|Mr John Murray||Non-Executive Chairman,Non-Executive Director||Sep 2016||
Mr John Murray
Non-Executive Chairman,Non-Executive Director
Mr Murray has 25 years experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original and leading venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has considerable experience as an investor and a non-executive director of high growth, technologybased companies. He possesses a broad understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also brings 12 years experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of a number of successful technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.
|Mr Ross Harricks||Non-Executive Director||Sep 2016||
Mr Ross Harricks
Mr Harricks has experience in the commercialisation of medical products which spans over forty years and over three continents. His experience includes the marketing and commercialising of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. In 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers. In Australia Mr Harricks has been a director of ResMed Limited and cofounder of AtCor Medical where he completed an Australian initial public offering in 2005 leading the company until 2007. He was a director of VentraCor from 2005 to 2009. Mr Harricks works with Australian medical and technology companies assisting in commercialisation of their products into the US and EU markets. His unique expertise and experience includes strategic advising on the best path to early international market endorsement and adoption, and on providing hands-on help with implementation in the American and European markets.
|Mr Adam Stuart Davey||Non-Executive Director||Sep 2014||
Mr Adam Stuart Davey
Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, ASX listings, asset sales and purchases, transaction due diligence and director duties. This has been achieved through holding various roles within different organisations, including chairman, managing director, non-executive director, major shareholder and corporate adviser to the board. Mr Davey is a non-executive director of Ensurance Limited and the Agency Group Australia Ltd.
|Iain McAdam||Chief Financial Officer||N/A|
PCK directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|15/09/21||Adam Davey||Issued||396,040||$0.05||$20,000||Issue of securities|
|15/09/21||Philip Daffas||Issued||3,960,396||$0.051||$200,000||Issue of securities|
|15/09/21||Ross Harricks||Issued||396,040||$0.05||$20,000||Issue of securities|
|15/09/21||John Murray||Issued||792,079||$0.051||$40,000||Issue of securities|
|10/09/20||Adam Davey||Issued||206,396||$0.097||$20,000||Issue of securities|
|10/09/20||Ross Harricks||Issued||206,396||$0.097||$20,000||Issue of securities|
|10/09/20||Philip Daffas||Issued||2,063,957||$0.097||$200,000||Issue of securities|
|10/09/20||John Murray||Issued||412,791||$0.097||$40,000||Issue of securities|
|29/07/20||Adam Davey||Buy||+93,327||$0.115||$10,733||Conversion of securities|
|29/07/20||Adam Davey||Exercise||93,327||$0.115||$10,733||Conversion of securities|
|29/07/20||Ross Harricks||Buy||+93,327||$0.214||$20,000||Conversion of securities|
|29/07/20||Ross Harricks||Exercise||93,327||$0.214||$20,000||Conversion of securities|
|29/07/20||John Murray||Buy||+186,654||$0.131||$24,465||Conversion of securities|
|29/07/20||John Murray||Exercise||186,654||$0.131||$24,465||Conversion of securities|
|13/12/19||Ross Harricks||Issued||93,327||$0.214||$20,000||Issue of securities|
|13/12/19||Philip Daffas||Issued||933,270||$0.214||$200,000||Issue of securities|
|13/12/19||John Murray||Issued||186,654||$0.214||$40,000||Issue of securities|
|13/12/19||Adam Davey||Issued||93,327||$0.214||$20,000||Issue of securities|
|27/11/19||Ross Harricks||Sell||+6,149,874||$0.20||($1,229,975)||On-market trade|
|27/11/19||John Murray||Sell||+12,299,749||$0.20||($2,459,950)||On-market trade|
|27/11/19||Adam Davey||Sell||+6,149,874||$0.20||($1,229,975)||On-market trade|
|27/11/19||Philip Daffas||Sell||+20,499,581||$0.20||($4,099,916)||On-market trade|
|22/11/19||Philip Daffas||Exercise||40,999,162||$0.02||$819,983||Exercise of options|
|22/11/19||Adam Davey||Buy||+12,299,748||$0.02||$245,995||Exercise of options|
|22/11/19||Ross Harricks||Buy||+12,299,748||$0.02||$245,995||Exercise of options|
|22/11/19||Adam Davey||Exercise||12,299,748||$0.02||$245,995||Exercise of options|
|22/11/19||John Murray||Buy||+24,599,497||$0.02||$491,990||Exercise of options|
|22/11/19||Ross Harricks||Exercise||12,299,748||$0.02||$245,995||Exercise of options|
|22/11/19||John Murray||Exercise||24,599,497||$0.02||$491,990||Exercise of options|
|22/11/19||Philip Daffas||Buy||+40,999,162||$0.02||$819,983||Exercise of options|
The current holdings of PCK directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Peters Investments Pty Ltd||26/09/2021||113,000,000||9.98|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.